Biotechnology company United Therapeutics (NASDAQ:UTHR) reported Q1 CY2025 results topping the market’s revenue expectations , with sales up 17.2% year on year to $794.4 million. Its GAAP profit ...

The results exceeded Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $6.29 per share. The drugmaker posted revenue of $794.4 ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results tomorrow afternoon. Here’s what ...

CEO Martine Rothblatt highlighted that United Therapeutics achieved record revenue for the quarter, marking the ninth such achievement in the past 12 quarters. She emphasized the strong ...

Good morning and welcome to the United Therapeutics Corporation first quarter 2025 corporate update. My name is Tobin and I will be your conference operator today. (Operator Instructions ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) reported Q1 CY2025 results , with sales up 17.2% year on year to $794 ...

Good morning and welcome to the United Therapeutics Corporation First Quarter 2025 Corporate Update. My name is Dorwin [ph] and I will be your conference operator today. All participants on the ...

United Therapeutics Corporation (UTHR) reported its first-quarter 2025 earnings, showcasing a strong financial performance that exceeded market expectations. The company posted an earnings per ...

United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. United Therapeutics’s quarterly revenue was up 17.2% on a year-over-year basis. During the same period last year ...

United Therapeutics Corporation (UTHR) reported its first-quarter 2025 earnings, showcasing a strong financial performance that exceeded market expectations. The company posted an earnings per share ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow morning. Here’s what to look for.